Navigation Links
Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
Date:2/11/2008

rates with our newer customers. To help, we recently launched an expanded CO-OP marketing program to give our customers more options to enhance their practice, and market the benefits and availability of the Urgent PC system to treat overactive bladder (OAB) symptoms to their patients. Our efforts and focus on the existing customer base will help us actively penetrate the market and further position Urgent PC to be the leading choice for effective, and patient-friendly treatment for OAB symptoms with minimal side effects."

For the nine months ended December 31, 2007, net sales of $9.7 million increased 71% from $5.7 million for the same period in the prior year. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales increased by approximately 64%.

For the nine months ended December 31, 2007, sales to customers in the U.S. increased to $5.5 million, compared to $752,000 in the same nine-month period last year. Sales to customers outside the U.S. for the nine months ended December 31, 2007 were $5.5 million, representing a 12% increase, compared to $4.9 million in the same nine-month period last year. Excluding the translation impact of fluctuations in foreign currency exchange rates, sales to customers outside of the U.S. increased by approximately 4%.

Non-GAAP operating loss, which excludes non cash charges attributed to SFAS 123 (R) stock options, and depreciation and amortization expenses, as set forth below and reconciled to GAAP operating loss, declined to approximately $466,000 and $1.5 million for the three and nine months ended December 31, 2007 respectively, from approximately $820,000 and $3.3 million for the respective year ago periods. Included in the three and nine months ended December 31, 2007 is a $214,000 charge attributed to the cost for exiting the lease of the manufacturing facility in Eindhoven, The Netherlands and severance pay. The decline in non-GAAP operating loss is attributed primaril
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Uroplasty to Host Third Quarter Conference Call on February 11
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 SPIE Fellow ... Physics and Optical Science and Director of the Center ... North Carolina at Charlotte, and co-founder and Chairman of ... serve as the 2015 Vice President of SPIE, the ... President Philip Stahl announced recent election results at the ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
... ... Delay, LEXINGTON, Mass., ... Glenn L. Cooper,MD, its chairman and chief executive officer is postponing his,previously-announced ... of the recent delay in the approval of NEBIDO(R)., Dr. Cooper ...
... Raymond J. De,Hont, Chairman and Chief Executive Officer ... Fybroc business unit has received,an order for approximately $500,000 ... second and third quarters of the Company,s current fiscal ... order Fybroc has received this year from the,Eastern European ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) today announced that ... million, newly issued 15% Convertible,Senior Notes due 2011, with ... warrant to purchase approximately 14.6 million shares of common ... This transaction constitutes a partial exercise of a previously ...
Cached Biology Technology:Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 2Met-Pro Corporation's Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000 3Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2
(Date:8/31/2014)... and accurate tool to diagnose tuberculosis in children, ... test (TAM-TB assay) is the first reliable immunodiagnostic ... test features excellent specificity, a similar sensitivity as ... blood test. The promising findings are a major ... particularly in tuberculosis-endemic regions. , The study has ...
(Date:8/31/2014)... the greatest challenges in modern medicine is developing drugs ... minimal toxicity and side-effects to the patient. Such properties ... drug molecule. Ideally, the drug should have a shape ... that it binds it with high specificity. Publishing in ... synthetic amino acid that can impact the 3D structure ...
(Date:8/31/2014)... study of satellite data from the last 19 years reveals ... around the coast of Antarctica to rise by 2cm more ... University of Southampton detected the rapid rise in sea-level by ... a million square kilometres. , The melting of ... shelves has contributed an excess of around 350 gigatonnes of ...
Breaking Biology News(10 mins):New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... June 28, 2013 -- A single systemic dose of ... in a preclinical animal model of kidney transplantation, according ... Medicine. Their findings, now available in the online version ... lay the foundation for eventual human trials of the ...
... the ,parrot dinosaur, is known from more than 1000 specimens from ... of east Asia. As part of his PhD thesis at ... the Institute for Vertebrate Paleontology in Beijing, carried out the intricate ... said: "Some of the bones from baby Psittacosaurus were ...
... multitude of microbes colonizing and thriving on flecks of ... flotilla of microbial communities that they have dubbed the ... Environmental Science & Technology , the scientists say ... ocean and raises a host of questions: How will ...
Cached Biology News:Dendritic cell therapy improves kidney transplant survival, Pitt team says 2Exploring dinosaur growth 2Scientists discover thriving colonies of microbes in ocean 'plastisphere' 2
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: